Switch to: Citations

Add references

You must login to add references.
  1. The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease.Timothy Daly & Stéphane Epelbaum - 2023 - American Journal of Bioethics Neuroscience 14 (3):332-335.
    It is a tale of two Pfizers. In 2018 they abandoned research into the leading cause of dementia, Alzheimer’s Disease (AD) (Hawkes 2018). In 2021, they developed the first vaccine for Covid-19 to re...
    Download  
     
    Export citation  
     
    Bookmark   1 citation